SCHEMBL648662

SCHEMBL648662

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc2[nH]ncc2c1)CC(C)(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
GSK3B P49841 4/20 0.35
CLK4 Q9HAZ1 4/20 0.35
DYRK3 O43781 2/20 0.35
CLK2 P49760 2/20 0.35
CDK5 Q00535 2/20 0.35
DYRK1A Q13627 2/20 0.35
TSHR P16473 1/20 0.35
CLK1 P49759 1/20 0.35
CLK3 P49761 1/20 0.35
CDK5R1 Q15078 1/20 0.35
DYRK2 Q92630 1/20 0.35
DYRK1B Q9Y463 1/20 0.35
CDC7 O00311 4/20 0.35
PRKACA P17612 3/20 0.35
CDK2 P24941 3/20 0.35
MAP4K4 O95819 2/20 0.35
PIM1 P11309 2/20 0.35
HIPK2 Q9H2X6 2/20 0.35
MKNK2 Q9HBH9 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650156 0.85 C5AR1 (0.42) C5AR1GSK3BCDK5DYRK1ATSHR
SCHEMBL648229 0.82 TRPA1 (0.39) GRIN2BTRPA1ROCK2ROCK1TRPM8
SCHEMBL648238 0.80 C5AR1 (0.38) C5AR1CDK5DYRK1ATSHRPRKACA
SCHEMBL650170 0.79 TRPA1 (0.37) GRIN2BTRPA1TRPM8TRPV1
SCHEMBL651784 0.78 C5AR1 (0.46) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL650200 0.78 C5AR1 (0.40) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL650365 0.77 C5AR1 (0.45) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL648637 0.77 C5AR1 (0.49) C5AR1GSK3BCLK4TSHRCDC7
SCHEMBL651094 0.76 TSHR (0.50) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135922 0.75 C5AR1 (0.49) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed